These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16012901)

  • 21. [Development and perspectives of community DOTS].
    Narita T; Kobayashi N
    Kekkaku; 2009 Apr; 84(4):187-201. PubMed ID: 19425394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silver nanoparticles in therapeutics: development of an antimicrobial gel formulation for topical use.
    Jain J; Arora S; Rajwade JM; Omray P; Khandelwal S; Paknikar KM
    Mol Pharm; 2009; 6(5):1388-401. PubMed ID: 19473014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies.
    Pouton CW; Porter CJ
    Adv Drug Deliv Rev; 2008 Mar; 60(6):625-37. PubMed ID: 18068260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and regulation of monoclonal antibody products: challenges and opportunities.
    Weinberg WC; Frazier-Jessen MR; Wu WJ; Weir A; Hartsough M; Keegan P; Fuchs C
    Cancer Metastasis Rev; 2005 Dec; 24(4):569-84. PubMed ID: 16408162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes.
    Petersson B; Schönwandt AB; Thornstfeldt P; Nedergaard H; Jensen MB; Thornstergaard PB; Norsell T; Bjerre J
    Clin Ther; 2008 May; 30(5):917-23. PubMed ID: 18555938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
    Flynn MA; McNeil DA; Maloff B; Mutasingwa D; Wu M; Ford C; Tough SC
    Obes Rev; 2006 Feb; 7 Suppl 1():7-66. PubMed ID: 16371076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Photostability and efficacy studies of topical formulations containing UV-filters combination and vitamins A, C and E.
    Gaspar LR; Campos PM
    Int J Pharm; 2007 Oct; 343(1-2):181-9. PubMed ID: 17614223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ocular inserts for controlled delivery of pefloxacin mesylate: preparation and evaluation.
    Sultana Y; Aqil M; Ali A
    Acta Pharm; 2005 Sep; 55(3):305-14. PubMed ID: 16375841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleation of crystals from solution: classical and two-step models.
    Erdemir D; Lee AY; Myerson AS
    Acc Chem Res; 2009 May; 42(5):621-9. PubMed ID: 19402623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and biopharmaceutical evaluation of extended release formulation of tramadol hydrochloride based on osmotic technology.
    Kumar P; Singh S; Mishra B
    Acta Pharm; 2009 Mar; 59(1):15-30. PubMed ID: 19304555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulation and delivery issues for monoclonal antibody therapeutics.
    Daugherty AL; Mrsny RJ
    Adv Drug Deliv Rev; 2006 Aug; 58(5-6):686-706. PubMed ID: 16839640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.
    Koren E; Smith HW; Shores E; Shankar G; Finco-Kent D; Rup B; Barrett YC; Devanarayan V; Gorovits B; Gupta S; Parish T; Quarmby V; Moxness M; Swanson SJ; Taniguchi G; Zuckerman LA; Stebbins CC; Mire-Sluis A
    J Immunol Methods; 2008 Apr; 333(1-2):1-9. PubMed ID: 18275969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ephemeral profiles of prescription drug and formulation tampering: evolving pseudoscience on the Internet.
    Cone EJ
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S31-9. PubMed ID: 16458455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal drug delivery system from laboratory to clinic.
    Kshirsagar NA; Pandya SK; Kirodian GB; Sanath S
    J Postgrad Med; 2005; 51 Suppl 1():S5-15. PubMed ID: 16519249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formulation considerations for the development of medications with abuse potential.
    Mansbach RS; Moore RA
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S15-22. PubMed ID: 16472940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Research design strategies to evaluate the impact of formulations on abuse liability.
    McColl S; Sellers EM
    Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S52-62. PubMed ID: 16554125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amended final report on the safety assessment of glyceryl dilaurate, glyceryl diarachidate, glyceryl dibehenate, glyceryl dierucate, glyceryl dihydroxystearate, glyceryl diisopalmitate, glyceryl diisostearate, glyceryl dilinoleate, glyceryl dimyristate, glyceryl dioleate, glyceryl diricinoleate, glyceryl dipalmitate, glyceryl dipalmitoleate, glyceryl distearate, glyceryl palmitate lactate, glyceryl stearate citrate, glyceryl stearate lactate, and glyceryl stearate succinate.
    Int J Toxicol; 2007; 26 Suppl 3():1-30. PubMed ID: 18273450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selecting and controlling API crystal form for pharmaceutical development--strategies and processes.
    Yin SX; Grosso JA
    Curr Opin Drug Discov Devel; 2008 Nov; 11(6):771-7. PubMed ID: 18946842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional proteomic screens in therapeutic protein drug discovery.
    Ilag LL
    Curr Opin Mol Ther; 2005 Dec; 7(6):538-42. PubMed ID: 16370376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.